Skip to main content
TipRanks
Go Ultimate75% OFF

3-D Matrix (7777) AI Stock Analysis

2 Followers
JP:7777

3-D Matrix

(TSE/TYO:7777)

Select Model
Rating:66Neutral
Price Target:JPY 352.00â–²(10.34% Upside)
Action:downgraded
Date:11/07/26

The company's financial turnaround and strong balance sheet are significant strengths, but the stock is under severe technical pressure, trading in a downtrend with deeply oversold momentum indicators. The low P/E ratio offers some valuation support, but the negative price trend is the primary drag on the score.

Positive Factors
Revenue GrowthRevenue has scaled sharply over several years and accelerated again most recently, providing evidence of expanding commercialization for the company’s peptide hemostat. If sustained, this growth can improve operating leverage and strengthen market reach across domestic and international surgical settings.
Negative Factors
Weak Cash ConversionWeak conversion of reported earnings into operating and free cash flow raises questions about earnings quality and the repeatability of recent profits. Persistently modest cash generation could restrict internally funded investment, increase reliance on financing, and limit flexibility during execution setbacks.

3-D Matrix (7777) vs. iShares MSCI Japan ETF (EWJ)

-25%0%25%50%75%100%125%150%175%JP:7777+3.91%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 310.35M
Dividend Yield
―
Average Volume (3M)
2.15M
Price to Earnings (P/E)
10.5
Beta (1Y)
1.83
Revenue Growth
55.91%
EPS Growth
―
Country
Japan
Employees
129
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

3-D Matrix Business Overview & Revenue Model

Company Description

3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, cell...

3-D Matrix Financial Statement Overview

Summary

Strong revenue growth and margin expansion, with a robust balance sheet featuring low debt. Cash flow has turned positive but lags net income, indicating some earnings quality concerns.

Income Statement

78Positive

Balance Sheet

92Very Positive

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMApr 2026Apr 2025Apr 2024Apr 2023Apr 2022
Income Statement
Total Revenue11.92B10.89B6.93B4.59B2.31B1.51B
Gross Profit9.48B8.57B4.42B3.09B1.29B661.01M
EBITDA2.54B4.17B-1.25B2.18B774.69M847.23M
Net Income3.69B4.16B-2.50B-255.50M-2.45B-1.89B
Balance Sheet
Total Assets9.40B9.80B6.51B5.89B5.83B5.61B
Cash, Cash Equivalents and Short-Term Investments1.69B2.83B1.58B1.36B1.17B2.85B
Total Debt600.00M600.00M2.94B4.17B4.37B3.67B
Total Liabilities2.18B3.00B4.30B5.53B5.30B4.15B
Stockholders Equity7.22B6.80B2.22B353.31M524.77M1.46B
Cash Flow
Free Cash Flow0368.89M-1.73B-1.90B-4.60B-2.92B
Operating Cash Flow0396.85M-1.71B-1.90B-4.59B-2.90B
Investing Cash Flow0-42.48M-33.30M-29.76M-81.50M-79.86M
Financing Cash Flow0786.49M2.01B2.06B2.96B4.66B

3-D Matrix Technical Analysis

Technical Analysis SentimentNegative
Last Price319.00

Price Trends

50DMA377.66Negative
100DMA364.47Negative
200DMA430.86Negative

Market Momentum

MACD-20.33Positive
RSI38.22Neutral
STOCH43.91Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Negative. The current price of 319.00 is below the 20-day moving average (MA) of 347.60, below the 50-day MA of 377.66, and below the 200-day MA of 430.86, indicating a bearish trend. The MACD of -20.33 indicates Positive momentum. The RSI at 38.22 is Neutral, neither overbought nor oversold. The STOCH value of 43.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7777.

3-D Matrix Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7777 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6678JP:667882OutperformJPY 18.47B12.39―5.95%17.11%23.02%
JP:7777JP:777766NeutralJPY 40.83B10.5063.82%―55.91%―
JP:6849JP:684963NeutralJPY 248.62B20.53―2.11%-0.18%-33.38%
JP:6523JP:652361NeutralJPY 156.61B10.865.56%3.41%2.74%145.33%
JP:7963JP:796359NeutralJPY 8.14B9.83―3.02%8.56%7.14%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4549JP:454950NeutralJPY 74.18B40.03―2.58%3.92%-52.01%

* Healthcare Sector Average

Performance Comparison

0%50%100%JP:7777JP:6523JP:4549JP:6678JP:6849JP:7963Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7777 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:77773-D Matrix 319.0010.003.24%
JP:6523PHC Holdings Corp.1230.00311.9333.98%
JP:4549Eiken Chemical Co., Ltd.2250.00-71.60-3.08%
JP:6678Techno Medica Co., Ltd.2167.00284.9515.14%
JP:6849Nihon Kohden Corporation1516.50-29.11-1.88%
JP:7963Koken Ltd.1655.00-138.64-7.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026